Materialise Q2 Preview: Anticipating Strong Medical Growth; Initiating With 'Buy'

  • I rate Materialise a 'buy' with a fair value of $8.83, driven by its unique integrated 3D printing software and hardware solutions. Materialise's strategic focus on software and medical segments strengthens its competitive edge, with medical now 47% of revenue and growing double digits. Recurring software revenue exceeds 80% in its segment, supporting margin expansion, customer retention, and reducing business cyclicality.